Trial of Solanezumab in Preclinical Alzheimer’s Disease von Sperling, Reisa A., Donohue, Michael C., Raman, Rema, Rafii, Michael S., Johnson, Keith, Masters, Colin L., van Dyck, Christopher H., Iwatsubo, Takeshi, Marshall, Gad A., Yaari, Roy, Mancini, Michele, Holdridge, Karen C., Case, Michael, Sims, John R., Aisen, Paul S.

Volltext

Targeting amyloid β in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies von Holdridge, Karen C, Yaari, Roy, Hoban, Deirdre B, Andersen, Scott, Sims, John R

Volltext

A novel approach to delayed-start analyses for demonstrating disease-modifying effects in Alzheimer's disease von Liu-Seifert, Hong, Andersen, Scott W, Lipkovich, Ilya, Holdridge, Karen C, Siemers, Eric

Volltext

Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention Trials von Aschenbrenner, Andrew J, Hassenstab, Jason, Wang, Guoqiao, Li, Yan, Xiong, Chengjie, McDade, Eric, Clifford, David B, Salloway, Stephen, Farlow, Martin, Yaari, Roy, Cheng, Eden Y J, Holdridge, Karen C, Mummery, Catherine J, Masters, Colin L, Hsiung, Ging-Yuek, Surti, Ghulam, Day, Gregory S, Weintraub, Sandra, Honig, Lawrence S, Galvin, James E, Ringman, John M, Brooks, William S, Fox, Nick C, Snyder, Peter J, Suzuki, Kazushi, Shimada, Hiroyuki, Gräber, Susanne, Bateman, Randall J

Volltext

Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia von Svaldi, Diana Otero, Higgins, Ixavier A., Holdridge, Karen C., Yaari, Roy, Case, Michael, Bracoud, Luc, Scott, David, Shcherbinin, Sergey, Sims, John R.

Volltext

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years von Liu-Seifert, Hong, Siemers, Eric, Holdridge, Karen C, Andersen, Scott W, Lipkovich, Ilya, Carlson, Christopher, Sethuraman, Gopalan, Hoog, Sharon, Hayduk, Roza, Doody, Rachelle, Aisen, Paul

Volltext

Statistical properties of continuous composite scales and implications for drug development von Liu-Seifert, Hong, Andersen, Scott, Case, Michael, Sparks, JonDavid, Holdridge, Karen C., Wessels, Alette M., Hendrix, Suzanne, Aisen, Paul, Siemers, Eric

Volltext

Delayed-start analyses of up to 3.5 years in the phase 3 solanezumab expedition program in mild Alzheimer's disease von Liu-Seifert, Hong, Aisen, Paul S, Andersen, Scott W, Holdridge, Karen C, Siemers, Eric R

Volltext

Evaluation of dose‐dependent treatment effects after mid‐trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherite... von Wang, Guoqiao, Li, Yan, Xiong, Chengjie, McDade, Eric, Clifford, David B., Mills, Susan L., Santacruz, Anna M., Aschenbrenner, Andrew J., Hassenstab, Jason, Benzinger, Tammie L.S., Gordon, Brian A., Fagan, Anne M., Coalier, Kelley A., Libre‐Guerra, Jorge J., McCullough, Austin, Joseph‐Mathurin, Nelly, Chen, Charles D., Mummery, Catherine, Wendelberger, Barbara A., Gauthier, Serge, Masellis, Mario, Holdridge, Karen C., Yaari, Roy, Chatterjee, Saptarshi, Sims, John, Delmar, Paul, Kerchner, Geoffrey A., Bittner, Tobias, Hofmann, Carsten, Bateman, Randall J.

Volltext

Decentralized approaches in TRAILBLAZER-ALZ 3 (P7-6.006) von Yaari, Roy, Holdridge, Karen, Ferguson, Margaret, Wessels, Alette, Sims, John

Volltext

Safety of solanezumab in the expedition-ext study up to 2 years in a mild to moderate Alzheimer’s disease population von Carlson, Christopher D, Sethuraman, Gopalan, Andersen, Scott W, Holdridge, Karen C, Hoog, Sharon L, Hayduk, Roza, Siemers, Eric R

Volltext

Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals von Sperling, Reisa A, Donohue, Michael C, Raman, Rema, Sun, Chung-Kai, Yaari, Roy, Holdridge, Karen, Siemers, Eric, Johnson, Keith A, Aisen, Paul S

Volltext

Seizure risk in patients with attention‐deficit‐hyperactivity disorder treated with atomoxetine von Wernicke, Joachim F, Holdridge, Karen Chilcott, Jin, Ling, Edison, Timothy, Zhang, Shuyu, Bangs, Mark E, Allen, Albert J, Ball, Susan, Dunn, David

Volltext

Function and clinical meaningfulness of treatments for mild Alzheimer's disease von Siemers, Eric, Holdridge, Karen Chilcott, Sundell, Karen L, Liu-Seifert, Hong

Volltext

Implementation of Home Infusions in a Multinational Preclinical Alzheimer’s Disease Study von Velona, Isabella, Yaari, Roy, Holdridge, Karen C., Brown, Cheryl Ann, Cohen, Paula, Shaffer‐Bacareza, Elizabeth, Arampatzidou, Maria, Lizzul, Nancy, Weiss, Ellen

Volltext

Neuroimaging Results and A4 in the Context of the LEARN Study von Sperling, Reisa A., Donohue, Michael C., Raman, Rema, Rafii, Michael S, Johnson, Keith A., Yaari, Roy, Mancini, Michele, Holdridge, Karen C., Case, Michael G., Sims, John R., Aisen, Paul S. S

Volltext

Delayed-Start Analyses of Solanezumab Phase 3 Studies in Mild Alzheimer’s Disease (P7.108) von Liu-Seifert, Hong, Andersen, Scott, Holdridge, Karen, Siemers, Eric

Volltext

Longitudinal cerebrospinal fluid phosphorylated tau181 and total tau do not reflect tau PET retention in dominantly inherited Alzheimer disease von McDade, Eric, Wang, Guoqiao, Li, Yan, Gordon, Brian A., Benzinger, Tammie L.S., Fagan, Anne M., Llibre‐Guerra, Jorge J, Cruchaga, Carlos, Clifford, David B., Xiong, Chengjie, Perrin, Richard J., Bittner, Tobias, Holdridge, Karen C., Yaari, Roy, Bateman, Randall J.

Volltext

P4‐290: IMAGING BIOMARKER TRAJECTORIES OF THE MILD AD DEMENTIA POPULATION IN THE EXPEDITION3 TRIAL von Shcherbinin, Sergey, Jaeger, Ralf, Charil, Arnaud, Holdridge, Karen C., Longley, Harriet, Yaari, Roy, Sims, John R., Mintun, Mark A.

Volltext

IMAGING BIOMARKER TRAJECTORIES OF THE MILD AD DEMENTIA POPULATION IN THE EXPEDITION3 TRIAL von Shcherbinin, Sergey, Jaeger, Ralf, Charil, Arnaud, Holdridge, Karen C., Longley, Harriet, Yaari, Roy, Sims, John R., Mintun, Mark A.

Volltext